Immunoabsorption Therapy for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Retrospective Study

IntroductionThe elimination of myelin oligodendrocyte glycoprotein (MOG) antibodies using immunoadsorption (IA) is a therapeutic approach, but has not yet been specifically evaluated in MOG antibody-associated disease (MOGAD). This study aimed to provide evidence on the efficacy and safety of IA therapy for MOGAD.MethodsThis retrospective study included patients diagnosed with MOGAD, who were treated with IA. Clinical data of the patients were collected. The extended disability score scale (EDSS) before and after IA therapy was used to evaluate neurological status.ResultsSix patients aged 14-53 years were enrolled in this study. Each patient received 3-7 sessions of IA therapy. Half of the patients showed significant clinical improvement after IA, with EDSS scores decreasing by more than 1.0, whereas the other patients were unresponsive to IA. Partial remission of visual acuity was obtained in three of the four patients with visual impairment. Repeated detection of MOG antibodies in one case showed that the titer declined from 1:100 to 1:32 after five sessions of IA. Only one episode of mild hypotension was observed in 29 IA sessions.ConclusionIA therapy may be a potential treatment option for patients with MOGAD.